Alzamend Neuro, Inc. (ALZN): Total Liabilities
$1.35M
As of 2026-04-30
$2.74M
As of 2026-07-31
-22.3%
3-year compound annual growth
+8.4%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2026-04-30 | $1.35M | +112.1% | 2026-07-22, Balance as of period end |
| 2025-04-30 | $634.8K | -80.3% | 2026-07-22, Balance as of period end |
| 2024-04-30 | $3.23M | +12.4% | 2025-07-22, Balance as of period end |
| 2023-04-30 | $2.87M | +146.4% | 2024-07-30, Balance as of period end |
| 2022-04-30 | $1.16M | +29.5% | 2023-07-27, Balance as of period end |
| 2021-04-30 | $899.6K | n/a | 2022-07-19, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | 2026-04-30 | $1.35M | +112.1% |
| Inhibitor Therapeutics, Inc. (INTI) | 2025-12-31 | $3.80M | +2.5% |
| Accustem Sciences Inc. (ACUT) | 2025-12-31 | $4.95M | +47.2% |
| Artelo Biosciences, Inc. (ARTL) | 2025-12-31 | $4.07M | +121.2% |
| BullFrog AI Holdings, Inc. (BFRG) | 2025-12-31 | $672.0K | +14.3% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $20.33M | +127.9% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.10M | +34.7% |
| Alaunos Therapeutics, Inc. (TCRT) | 2025-12-31 | $813.0K | +17.5% |
| InMed Pharmaceuticals Inc. (INM) | 2026-06-30 | $1.96M | -8.9% |
Compare ALZN, INTI, ACUT, ARTL side by side · Screen every company in Pharmaceutical Preparations ↗